DE69317578D1 - Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen - Google Patents

Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen

Info

Publication number
DE69317578D1
DE69317578D1 DE69317578T DE69317578T DE69317578D1 DE 69317578 D1 DE69317578 D1 DE 69317578D1 DE 69317578 T DE69317578 T DE 69317578T DE 69317578 T DE69317578 T DE 69317578T DE 69317578 D1 DE69317578 D1 DE 69317578D1
Authority
DE
Germany
Prior art keywords
riluzole
pct
treating traumatic
date
traumatic neurological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69317578T
Other languages
English (en)
Other versions
DE69317578T2 (de
Inventor
Adam Doble
Erik Louvel
Jeremy Pratt
Jean-Marie Stutzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Application granted granted Critical
Publication of DE69317578D1 publication Critical patent/DE69317578D1/de
Publication of DE69317578T2 publication Critical patent/DE69317578T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
DE69317578T 1992-12-16 1993-12-10 Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen Expired - Lifetime DE69317578T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9215148A FR2699077B1 (fr) 1992-12-16 1992-12-16 Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
PCT/FR1993/001229 WO1994013288A1 (fr) 1992-12-16 1993-12-10 Application du riluzole dans le traitement de lesions neurologiques liees a des traumatismes

Publications (2)

Publication Number Publication Date
DE69317578D1 true DE69317578D1 (de) 1998-04-23
DE69317578T2 DE69317578T2 (de) 1998-07-23

Family

ID=9436652

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69317578T Expired - Lifetime DE69317578T2 (de) 1992-12-16 1993-12-10 Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen

Country Status (23)

Country Link
US (1) US5830907A (de)
EP (3) EP0674518A1 (de)
JP (3) JPH08504429A (de)
KR (3) KR950703965A (de)
AT (1) ATE164067T1 (de)
AU (3) AU5653994A (de)
CA (3) CA2151604C (de)
CZ (3) CZ284420B6 (de)
DE (1) DE69317578T2 (de)
DK (1) DK0674512T3 (de)
ES (1) ES2113635T3 (de)
FR (1) FR2699077B1 (de)
GR (1) GR3026403T3 (de)
HU (3) HU217133B (de)
IL (3) IL108051A (de)
MX (3) MX9307884A (de)
NO (3) NO952228L (de)
PL (3) PL309348A1 (de)
RU (1) RU2142800C1 (de)
SK (3) SK78595A3 (de)
UA (1) UA41906C2 (de)
WO (3) WO1994013288A1 (de)
ZA (3) ZA939401B (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
FR2733684B1 (fr) 1995-05-03 1997-05-30 Cird Galderma Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
KR100382619B1 (ko) * 1997-09-05 2003-05-09 글락소 그룹 리미티드 2,3-디아릴-피라졸로[1,5-ｂ]피리다진 유도체, 그의 제조방법 및 시클로옥시게나제 2(ｃｏｘ-2) 억제제로서의 용도
GB9808015D0 (en) * 1998-04-15 1998-06-17 United Medical And Dental Scho Protection of the nervous system from the effects of inflammatory disease
US6150423A (en) * 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
FR2787028B1 (fr) 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
CA2372077A1 (en) * 1999-04-29 2000-11-09 Centre National De La Recherche Scientifique (C.N.R.S.) A method for the prevention of ischemic spinal cord injury caused by aortic crossclamping
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007022568A1 (en) 2005-08-25 2007-03-01 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
AU2013257742A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
AU2013257706A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013175357A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
CN104603097A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗多发性硬化症的组合物和方法
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9765020B2 (en) 2012-05-23 2017-09-19 Cellix Bio Private Limited Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
AU2013311349A1 (en) 2012-09-08 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (de) 2013-06-04 2018-09-05 Cellixbio Private Limited Zusammensetzungen und verfahren zur behandlung von diabetes und prädiabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
WO2016098119A1 (en) 2014-10-27 2016-06-23 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
EP3242869B1 (de) 2015-01-06 2021-10-27 Cellixbio Private Limited Zusammensetzungen und verfahren zur behandlung von entzündungen und schmerzen
EP3353145B1 (de) 2015-09-23 2022-09-28 XWPharma Ltd. Prodrugs von gamma-hydroxybuttersäure, zusammensetzungen und verwendungen davon
CA3058216C (en) 2017-03-30 2023-08-15 Xw Laboratories Inc. Bicyclic heteroaryl derivatives and preparation and uses thereof
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
US20200289476A1 (en) * 2017-11-28 2020-09-17 University Of Houston System Liquid formulations of riluzole for oral and intravenous use
JP6996029B2 (ja) 2018-09-30 2022-01-17 エックスダブリューファルマ リミテッド ニューロンヒスタミン受容体－３アンタゴニストとしての化合物およびその使用
CN115244028A (zh) 2019-12-20 2022-10-25 凯瑞康宁生物工程有限公司 4-缬氨酰氧基丁酸的合成方法
EP4167971A1 (de) 2020-06-18 2023-04-26 XWPharma Ltd. Granulate mit kontrollierter freisetzung von wasserlöslichen pharmazeutischen wirkstoffen
JP2023537192A (ja) 2020-06-18 2023-08-31 エックスダブリューファーマ リミテッド 水溶性医薬品有効成分の医薬造粒物
US11896573B2 (en) 2020-07-24 2024-02-13 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
EP4225274A1 (de) 2020-10-05 2023-08-16 XWPharma Ltd. Zusammensetzungen aus gamma-hydroxybuttersäurederivaten mit modifizierter freisetzung
WO2022198033A1 (en) 2021-03-19 2022-09-22 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS234018B2 (en) * 1979-06-01 1985-03-14 Wellcome Found Method of 3,5-diammino-6-1,2,4-triazine derivatives making
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US4918090A (en) * 1988-01-25 1990-04-17 Warner-Lambert Company Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents
US5240948A (en) * 1989-12-13 1993-08-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. 3-(3-alkylthiopropyl)benzothiazoline derivatives, their preparation and the medicament containing them
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
EP0940139B1 (de) * 1991-02-08 2005-02-02 Scion Pharmaceuticals, Inc. Substituierte Guanidine und Derivate hiervon als Modulatoren der Freisetzung von Neurotransmittern und neue Methode zur Identifizierung von Inhibitoren der Neurotransmitter-Freisetzung
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

Also Published As

Publication number Publication date
CA2151604A1 (fr) 1994-06-23
SK78795A3 (en) 1996-05-08
EP0674518A1 (de) 1995-10-04
NO952229L (no) 1995-06-06
CA2151604C (fr) 2005-09-20
RU2142800C1 (ru) 1999-12-20
HUT71812A (en) 1996-02-28
HU9501753D0 (en) 1995-08-28
CZ154795A3 (en) 1995-11-15
AU5654094A (en) 1994-07-04
CA2151601A1 (fr) 1994-06-23
JP3712239B2 (ja) 2005-11-02
KR950703965A (ko) 1995-11-17
SK78595A3 (en) 1996-05-08
UA41906C2 (uk) 2001-10-15
ZA939399B (en) 1994-08-22
SK279759B6 (sk) 1999-03-12
JPH08504428A (ja) 1996-05-14
PL309348A1 (en) 1995-10-02
NO952228D0 (no) 1995-06-06
JPH08504430A (ja) 1996-05-14
US5830907A (en) 1998-11-03
FR2699077A1 (fr) 1994-06-17
KR100298808B1 (ko) 2001-11-22
SK78695A3 (en) 1996-05-08
EP0674512A1 (de) 1995-10-04
NO307027B1 (no) 2000-01-31
AU678795B2 (en) 1997-06-12
WO1994013288A1 (fr) 1994-06-23
DE69317578T2 (de) 1998-07-23
CZ284420B6 (cs) 1998-11-11
GR3026403T3 (en) 1998-06-30
MX9307883A (es) 1994-06-30
IL108051A (en) 1999-05-09
IL108052A0 (en) 1994-04-12
PL309346A1 (en) 1995-10-02
HU217133B (hu) 1999-11-29
FR2699077B1 (fr) 1995-01-13
EP0674512B1 (de) 1998-03-18
NO952228L (no) 1995-06-06
IL108053A0 (en) 1994-04-12
WO1994013296A1 (fr) 1994-06-23
ATE164067T1 (de) 1998-04-15
ZA939400B (en) 1994-08-19
NO952230L (no) 1995-06-06
ES2113635T3 (es) 1998-05-01
MX9307882A (es) 1994-06-30
HUT71814A (en) 1996-02-28
KR950703954A (ko) 1995-11-17
ZA939401B (en) 1994-08-19
HUT71839A (en) 1996-02-28
PL309347A1 (en) 1995-10-02
IL108051A0 (en) 1994-04-12
CZ154695A3 (en) 1995-11-15
NO952229D0 (no) 1995-06-06
AU5702094A (en) 1994-07-04
MX9307884A (es) 1994-06-30
EP0674520A1 (de) 1995-10-04
CA2151603A1 (fr) 1994-06-23
HU9501752D0 (en) 1995-08-28
DK0674512T3 (da) 1998-05-25
AU5653994A (en) 1994-07-04
WO1994013298A1 (fr) 1994-06-23
KR950703968A (ko) 1995-11-17
CZ154595A3 (en) 1995-11-15
JPH08504429A (ja) 1996-05-14
HU9501751D0 (en) 1995-08-28
NO952230D0 (no) 1995-06-06

Similar Documents

Publication Publication Date Title
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69526937T2 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE69310528D1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
DE69800859T2 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
ATE200624T1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
ATE200865T1 (de) Verwendung von phosphorderivaten von alkaloiden zur behandlung von endokrinopathien

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS PHARMA S.A., ANTONY, FR

8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC